As of 22 January, 19 of the 23 patients who have received treatment are still alive, with the longest evaluable survival ...

At study entry, patients demonstrated immune compromise consistent with prior standard of care, including radiation and alkylating chemotherapy. The baseline mean absolute lymphocyte count (ALC) was ...

An investigational drug for glioblastoma more than doubled survival and progression-free time compared to standard rates, reported a new study published in Nature Communications. Glioblastoma is the ...

18F-DOPA PET-guided proton beam therapy improved overall survival in older glioblastoma patients, with a median OS of 13.1 months and no grade 4 adverse events. The hypofractionated regimen, completed ...

Please provide your email address to receive an email when new articles are posted on . The 3.3-month improvement in median OS in the investigational arm did not reach statistical significance.

Reoperation in recurrent glioblastoma patients may improve progression-free and overall survival, especially when tumors are in non-eloquent, accessible brain regions. Factors like age, gender, tumor ...

Glioblastoma multiforme is an aggressive brain tumor that mainly affects adults. Approximately 30,000 people in the U.S. are diagnosed with GBM every year and patients have a 5-year survival rate of 7 ...

At study entry, patients demonstrated immune compromise consistent with prior standard of care, including radiation and ...